1Suttner,SW,Boldt J.Natriuretic peptide system:physilolgy and clinical utility.Curr Opin Crit Care,2004,10:336-341.
2Austin PC,Mamdani MM,Jaakkimainen L,et al.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure.A randomized controlled trial.JAMA,2002,287:1531-1540.
3Yang CW,Saltaberg MT,Berkowitz RL,et al.Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting(from the FUSION I trial).Am J Cardiol,2004,94:595-601.
4Abraham WT,Cheng ML,Smoluk G,et al.Clinical and hemodynamic effects of nesiritide(B-type natriuretic peptide)in patients with decompensated heart failure receiving beta blockers.Congest Heart Fail,2005,11:59-64.
6Peacock WF,Emerman CL,Silver MA.Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure.Am J Emerg Med,2005,23:327-331.
7Abraham WT,Adams KF,Fonarow GC,et al.In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications:an analysis from the Acute Decompensated Heart Failure National Registry(ADHERE).J Am Coll Cardiol,2005,46:57-64.
8Burger AJ.A review of the renal and neurohormonal effects of B-type natriuretic peptide.Congest Heart Faill,2005,11:30-38.
9Sackner-Bernstein JD,Skopicki HA,Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.Circulation,2005,111:1487-1491.
10Sackner-Bernstein JD,Kowalski M,Fox M,et al.Short-term risk of death after treatment with nesiritide for decompensated heart failure.JAMA,2005,293:1900-1905.
